Myriad Genetics Inc. reported that the analytical validation of its FirstGene Multiple Prenatal Screen has been published in *Clinical Chemistry*. The study evaluated nearly 500 samples across test components including fetal aneuploidy screening, RhD compatibility, and screening for 19 recessive single-gene conditions, and reported analytical sensitivity of at least 98.2% and analytical specificity of at least 99.0% for each component. The results have already been presented via publication in the journal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9657602-en) on February 19, 2026, and is solely responsible for the information contained therein.